The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 50.20
Bid: 49.90
Ask: 50.20
Change: 1.60 (3.29%)
Spread: 0.30 (0.601%)
Open: 48.45
High: 51.10
Low: 47.20
Prev. Close: 48.60
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appoints Prof. Clark Chair of ESG Ethics Committee

6 Jul 2020 07:00

RNS Number : 0545S
IP Group PLC
06 July 2020
 

FOR RELEASE ON

 06 July 2020

 

 

IP Group plc appoints Gordon Clark, Emeritus Professor, Oxford University, and long-term investment expert, as Chair of ESG Ethics Committee

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, is pleased to announce that it has appointed Professor Gordon Clark, Senior Consultant and Emeritus Professor of the Smith School of Enterprise and the Environment, Oxford University, as Chair of its Ethics Committee.

 

The Group's Ethics Committee has been set up to oversee IP Group's Ethical Investment Framework which sets out the Group's approach to responsible investing. Professor Clark will Chair the Committee, providing advice on investments when required as well as reviewing the framework and ensuring compliance. The Committee will also comprise a member of the executive team, two partners representing the Group's investment focus areas of life sciences and technology as well as representation from the risk and compliance department. Professor Clark will report to the IP Group plc Board on matters regarding the Ethical Investment Framework and Ethics Committee but is not a Board member.

 

Professor Clark is one of the most influential academics in the world in the field of investment management, particularly in relation to long-term ESG factors such as environmental performance.

 

Alan Aubrey, Chief Executive of IP Group plc and Board representative for ESG, said: "Responsible investing has long been at the heart of IP Group's ethos, as we aim to address some of the world's most pressing challenges and generate positive social and environmental impact alongside financial returns. We are very pleased to have Professor Clark working with IP Group as we formalise our approach to responsible investment. The recent COVID-19 outbreak has further brought to light the role of investors and companies in ensuring best practice in environmental, social and governance issues. Professor Clark has an excellent insight into this subject and we look forward to working with him."

 

Professor Clark said: "I look forward to working with IP Group on its ESG and ethics initiative. It's a remarkable time, of course, with the COVID-19 challenge and the issue of climate change - two particularly pressing and substantial issues, which both investors and the public are increasingly vocal about. I am pleased to be part of IP Group's work and contributing to a better understanding of the role that the company can play in addressing these issues."

 

As well as serving as a Professorial Fellow at St Edmund Hall, Oxford, Professor Clark is also co-Director of the Zurich-Oxford research programme at the Smith School of Enterprise and the Environment. He has been Sir Louis Matheson Distinguished Visiting Professor at Monash University's Faculty of Business and Economics (Melbourne) and is currently a Visiting Scholar at Stanford University's Global Projects Centre (part of the Faculty of Engineering). 

 

IP Group aims to address some of the world's most pressing challenges through the companies and innovation we back and support, allowing us to generate positive social and environmental impact alongside financial returns.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

Ashleigh Lezard

+44 (0) 7979 853802

+44 (0) 7920 510065

Charlotte Street Partners

 

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAKKPBQPBKDFOK
Date   Source Headline
18th Oct 20182:00 pmRNSAmgen invests £50m in Oxford Nanopore Technologies
15th Oct 20187:00 amRNSPortfolio co Garrison completes £22.9m financing
8th Oct 20187:07 amRNSPortfolio co Diurnal headline data for Chronocort
19th Sep 20189:51 amRNSDirector/PDMR Shareholding
17th Sep 20184:58 pmRNSDirector/PDMR Shareholding
17th Sep 20184:38 pmRNSDirector/PDMR Shareholding
17th Sep 201812:12 pmRNSDirector/PDMR Shareholding
17th Sep 20187:00 amRNSAppointment of Chairman; Board changes
31st Aug 20189:55 amRNSHolding(s) in Company
30th Aug 20187:00 amRNSGenomics announces Vertex leads £25m financing
29th Aug 20186:29 pmRNSIP Group plc -SAYE scheme
21st Aug 20187:06 amRNSCeres signs agreement with Bosch; £9m investment
10th Aug 20187:11 amRNSArtios Pharma completes £65m financing
31st Jul 20188:40 amRNSTR-1: NOTIFICATION
25th Jul 20187:00 amRNSHalf-yearly results
6th Jul 20187:00 amRNSNotification of Major Interest in Shares
4th Jul 20182:40 pmRNSCeres Power announces £20m fundraising
2nd Jul 20187:00 amRNSHolding(s) in Company
27th Jun 20187:30 amRNSCarisma announces $53m Series A funding round
27th Jun 20187:00 amRNSNotification of Major Interest in Shares
22nd Jun 201810:00 amRNSAppointment of Joint Broker
18th Jun 20181:37 pmRNSResult of AGM
7th Jun 20186:00 pmRNSHolding(s) in Company
6th Jun 20189:26 amRNSMicrobiotica signs collaboration worth up to $534m
16th May 201810:49 amRNSPortfolio co Ceres partners with Weichai Power
16th May 20187:00 amRNSNotice of AGM; Annual Report
11th May 20187:00 amRNSDirector/PDMR Shareholding
10th May 20186:18 pmRNSDirector/PDMR Shareholding
9th May 20185:31 pmRNSDirector share purchase
4th May 20187:00 amRNSBoard changes
30th Apr 20187:00 amRNSTotal Voting Rights
16th Apr 20185:45 pmRNSDirector/PDMR Shareholding
12th Apr 20189:19 amRNSEnterprise Therapeutics raises £29m
5th Apr 20181:12 pmRNSIP Group plc - Issue of Equity
4th Apr 201811:46 amRNSIP Group plc - Director/PDMR share purchase
29th Mar 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSOxford Nanopore announces £100m fundraising
17th Jan 201811:53 amRNSHolding(s) in Company
10th Jan 20189:12 amRNSHolding(s) in Company
2nd Jan 20187:00 amRNSTotal Voting Rights
18th Dec 201710:15 amRNSAutifony signs Eur627.5m agreement with BI
15th Dec 201712:50 pmRNSDiurnal receives positive CHMP opinion for Alkindi
14th Dec 20174:48 pmRNSDirectorate Change
13th Dec 20172:27 pmRNSIssue of Equity
8th Dec 20177:05 amRNSMirriad raises £26.2m; proposed admission to AIM
6th Dec 20172:32 pmRNSIssue of Equity
30th Nov 201712:40 pmRNSTotal Voting Rights
27th Nov 20176:27 pmRNSIssue of Equity
22nd Nov 20175:50 pmRNSHolding(s) in Company
22nd Nov 20173:23 pmRNSIssue of Equity

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.